The Filings Report

GLOBUS MEDICAL INC

GMEDNYSECIK 1237831Healthcare / Medical Devicesfiscal year ends December63 quarters since 2011

Revenue, Q3 FY2026
$764M
−0.7% on Q3 FY2025
Net income
$141M
+18.7% on Q3 FY2025
Free cash flow
$225M
+5.1% on Q3 FY2025
Diluted EPS
$1.04
+18.2% on Q3 FY2025
Revenue, TTM
$3.1B
trailing four quarters
Net margin, TTM
17.8%
net income $558M
Free cash flow, TTM
$767M
$926M less $159M capex
Cash and equivalents
$441M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+0.5%
136M diluted weighted shares (no single count on the cover), Sep 30, 2026
Buybacks, TTM
$324M
3.4% of market value
Dividends, TTM
—
no yield
Market value
$9.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, GLOBUS MEDICAL INC reported revenue of $764M, −0.7% on Q3 FY2025, and net income of $141M (+18.7%). Operating margin was 23.2%. Free cash flow, operating cash flow less capital expenditures, was $225M ($265M less $40M). Diluted earnings per share were $1.04.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

GMED daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $74.10 · H $75.63 · L $70.40 · C $71.05 · −12.76% on the dayOver the range: +15.14%, Nov 7, 2025 to Nov 6, 2026
$69$77$86$95$103Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 5, 2026.

Revenue and net incomeRevenueNet income
−$250M$0$250M$500M$750M$1.0BQ4'22, Revenue: $274MQ4'22, Net income: $50MQ4'22Q1'23, Revenue: $277MQ1'23, Net income: $49MQ1'23Q2'23, Revenue: $292MQ2'23, Net income: $58MQ2'23Q3'23, Revenue: $384MQ3'23, Net income: $998KQ3'23Q4'23, Revenue: $617MQ4'23, Net income: $15MQ4'23Q1'24, Revenue: $607MQ1'24, Net income: −$7MQ1'24Q2'24, Revenue: $630MQ2'24, Net income: $32MQ2'24Q3'24, Revenue: $626MQ3'24, Net income: $52MQ3'24Q4'24, Revenue: $657MQ4'24, Net income: $27MQ4'24Q1'25, Revenue: $598MQ1'25, Net income: $75MQ1'25Q2'25, Revenue: $745MQ2'25, Net income: $203MQ2'25Q3'25, Revenue: $769MQ3'25, Net income: $119MQ3'25Q4'25, Revenue: $826MQ4'25, Net income: $141MQ4'25Q1'26, Revenue: $760MQ1'26, Net income: $124MQ1'26Q2'26, Revenue: $790MQ2'26, Net income: $152MQ2'26Q3'26, Revenue: $764MQ3'26, Net income: $141MQ3'26−$250M$0$250M$500M$750M$1.0BQ4'22, Revenue: $274MQ4'22, Net income: $50MQ4'22Q1'23, Revenue: $277MQ1'23, Net income: $49MQ1'23Q2'23, Revenue: $292MQ2'23, Net income: $58MQ2'23Q3'23, Revenue: $384MQ3'23, Net income: $998KQ3'23Q4'23, Revenue: $617MQ4'23, Net income: $15MQ4'23Q1'24, Revenue: $607MQ1'24, Net income: −$7MQ1'24Q2'24, Revenue: $630MQ2'24, Net income: $32MQ2'24Q3'24, Revenue: $626MQ3'24, Net income: $52MQ3'24Q4'24, Revenue: $657MQ4'24, Net income: $27MQ4'24Q1'25, Revenue: $598MQ1'25, Net income: $75MQ1'25Q2'25, Revenue: $745MQ2'25, Net income: $203MQ2'25Q3'25, Revenue: $769MQ3'25, Net income: $119MQ3'25Q4'25, Revenue: $826MQ4'25, Net income: $141MQ4'25Q1'26, Revenue: $760MQ1'26, Net income: $124MQ1'26Q2'26, Revenue: $790MQ2'26, Net income: $152MQ2'26Q3'26, Revenue: $764MQ3'26, Net income: $141MQ3'26−$250M$0$250M$500M$750M$1.0BQ4'22, Revenue: $274MQ4'22, Net income: $50MQ1'23, Revenue: $277MQ1'23, Net income: $49MQ1'23Q2'23, Revenue: $292MQ2'23, Net income: $58MQ3'23, Revenue: $384MQ3'23, Net income: $998KQ3'23Q4'23, Revenue: $617MQ4'23, Net income: $15MQ1'24, Revenue: $607MQ1'24, Net income: −$7MQ1'24Q2'24, Revenue: $630MQ2'24, Net income: $32MQ3'24, Revenue: $626MQ3'24, Net income: $52MQ3'24Q4'24, Revenue: $657MQ4'24, Net income: $27MQ1'25, Revenue: $598MQ1'25, Net income: $75MQ1'25Q2'25, Revenue: $745MQ2'25, Net income: $203MQ3'25, Revenue: $769MQ3'25, Net income: $119MQ3'25Q4'25, Revenue: $826MQ4'25, Net income: $141MQ1'26, Revenue: $760MQ1'26, Net income: $124MQ1'26Q2'26, Revenue: $790MQ2'26, Net income: $152MQ3'26, Revenue: $764MQ3'26, Net income: $141MQ3'26

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300MQ4'22, Free cash flow: $46MQ4'22Q1'23, Free cash flow: $37MQ1'23Q2'23, Free cash flow: $17MQ2'23Q3'23, Free cash flow: $29MQ3'23Q4'23, Free cash flow: $82MQ4'23Q1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $26MQ2'24Q3'24, Free cash flow: $162MQ3'24Q4'24, Free cash flow: $193MQ4'24Q1'25, Free cash flow: $141MQ1'25Q2'25, Free cash flow: $31MQ2'25Q3'25, Free cash flow: $214MQ3'25Q4'25, Free cash flow: $202MQ4'25Q1'26, Free cash flow: $163MQ1'26Q2'26, Free cash flow: $177MQ2'26Q3'26, Free cash flow: $225MQ3'26$0$100M$200M$300MQ4'22, Free cash flow: $46MQ4'22Q1'23, Free cash flow: $37MQ1'23Q2'23, Free cash flow: $17MQ2'23Q3'23, Free cash flow: $29MQ3'23Q4'23, Free cash flow: $82MQ4'23Q1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $26MQ2'24Q3'24, Free cash flow: $162MQ3'24Q4'24, Free cash flow: $193MQ4'24Q1'25, Free cash flow: $141MQ1'25Q2'25, Free cash flow: $31MQ2'25Q3'25, Free cash flow: $214MQ3'25Q4'25, Free cash flow: $202MQ4'25Q1'26, Free cash flow: $163MQ1'26Q2'26, Free cash flow: $177MQ2'26Q3'26, Free cash flow: $225MQ3'26$0$100M$200M$300MQ4'22, Free cash flow: $46MQ1'23, Free cash flow: $37MQ1'23Q2'23, Free cash flow: $17MQ3'23, Free cash flow: $29MQ3'23Q4'23, Free cash flow: $82MQ1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $26MQ3'24, Free cash flow: $162MQ3'24Q4'24, Free cash flow: $193MQ1'25, Free cash flow: $141MQ1'25Q2'25, Free cash flow: $31MQ3'25, Free cash flow: $214MQ3'25Q4'25, Free cash flow: $202MQ1'26, Free cash flow: $163MQ1'26Q2'26, Free cash flow: $177MQ3'26, Free cash flow: $225MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ4'22Q1'23Q2'23Q3'23Q4'23Q1'24Q2'24Q3'24Q4'24, Cash and equivalents: $784MQ4'24Q1'25Q2'25Q3'25, Cash and equivalents: $372MQ3'25Q4'25, Cash and equivalents: $526MQ4'25Q1'26, Cash and equivalents: $561MQ1'26Q2'26, Cash and equivalents: $508MQ2'26Q3'26, Cash and equivalents: $441MQ3'26$0$200M$400M$600M$800MQ4'22Q1'23Q2'23Q3'23Q4'23Q1'24Q2'24Q3'24Q4'24, Cash and equivalents: $784MQ4'24Q1'25Q2'25Q3'25, Cash and equivalents: $372MQ3'25Q4'25, Cash and equivalents: $526MQ4'25Q1'26, Cash and equivalents: $561MQ1'26Q2'26, Cash and equivalents: $508MQ2'26Q3'26, Cash and equivalents: $441MQ3'26$0$200M$400M$600M$800MQ1'23Q3'23Q1'24Q3'24Q4'24, Cash and equivalents: $784MQ1'25Q3'25, Cash and equivalents: $372MQ3'25Q4'25, Cash and equivalents: $526MQ1'26, Cash and equivalents: $561MQ1'26Q2'26, Cash and equivalents: $508MQ3'26, Cash and equivalents: $441MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

GLOBUS MEDICAL INC income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue764790760826769745598657−0.7%
Cost of revenue233241234261253249195263−7.8%
Gross profit—————————
Research and development3536373638403333−9.3%
Selling, general and administrative288287298318314304243253−8.0%
Operating income178182150169137769760+29.3%
Other income (expense)677071127(36)−13.8%
Pretax income18319015716914418810425+27.3%
Income tax4238332925(15)28(2)+68.2%
Net income1411521241411192037527+18.7%
Diluted EPS ($)1.041.100.90—0.881.490.54—+18.2%
Diluted shares (millions)136137138—135136140——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

GLOBUS MEDICAL INC balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents441508561526372——784+18.7%
Short-term investments7687693119——106+306.1%
Total current assets2,1822,2162,1982,1261,9241,7301,7102,177+13.4%
Total assets5,5285,4885,4405,3035,0964,9614,7115,252+8.5%
Total current liabilities508479482498466425385856+9.0%
Long-term debt—————————
Total liabilities7327207077306976656231,074+5.0%
Stockholders’ equity4,7964,7694,7324,5734,3994,2964,0884,177+9.0%
Shares outstanding (millions)—134136135134135135138—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

GLOBUS MEDICAL INC cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow26521020224925078177210+6.2%
Capital expenditures4033404636473617+12.8%
Free cash flow (CFO − capex)22517716320221431141193+5.1%
Depreciation and amortization7069706971716668−1.0%
Share repurchases14313604540251901+257.4%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

GLOBUS MEDICAL INC income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Mar 16, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 5, 2013FY2011ended Dec 31, 2011filed Sep 19, 2012FY2010ended Dec 31, 2010filed Sep 19, 2012
Revenue2,9392,5191,5681,023958789785713636564545474434386331288
Cost of revenue9581,035548264239217180159150135——————
Gross profit——1,020759719572605554486429412364334311263234
Research and development14716412473978560554445363127282321
Selling, general and administrative1,178981644432408355355312268222210189183169140123
Operating income4801661332281721111721691621541721381021159788
Other income (expense)125(45)3215814181983100000
Pretax income6051211652431801261901891701571731391021159788
Income tax67184353312435326353604633413633
Net income5381031231901491021551561071041139269746154
Diluted EPS ($)3.920.751.071.851.441.011.521.541.101.081.170.970.730.800.670.60
Diluted shares (millions)1371381151031041011021019896969594929091

Balance sheet

GLOBUS MEDICAL INC balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Mar 16, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 5, 2013FY2011ended Dec 31, 2011filed Sep 19, 2012FY2010ended Dec 31, 2010filed Sep 19, 2012
Cash and equivalents526784————19514011967588290212143112
Short-term investments3110650296250187116200255———————
Total current assets2,1262,1771,915983865822687631620514545470417360259—
Total assets5,3035,2525,0862,0761,9571,6791,5321,3011,079928834704566447329—
Total current liabilities4988563921591401211119693808389684029—
Long-term debt————————————————
Total liabilities7301,0741,08823021617313011511196119118946147—
Stockholders’ equity4,5734,1773,9981,8461,7411,5061,4021,186968832715585472387282228
Shares outstanding (millions)13513813510010210010099979695959492——

Cash flow statement

GLOBUS MEDICAL INC cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 17, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 22, 2018FY2016ended Dec 31, 2016filed Mar 16, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 5, 2013FY2011ended Dec 31, 2011filed Sep 19, 2012FY2010ended Dec 31, 2010filed Sep 19, 2012
Operating cash flow7535212431782761991721821591481247993777671
Capital expenditures1651157874576471605141512524252212
Free cash flow (CFO − capex)589405165104219135101122108107735470525459
Depreciation and amortization27725314668706353424239242219181715
Share repurchases30086226144—105——————00100
Dividends paid————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
3 sales by 3 insiders; officers and directors $5M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$17M
14 sales by 7 insiders; officers and directors $17M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 4, 2026Rhoads Ann DDirectoropen-market sale10b5-15,000$85.00$425K35,384Nov 5, 2026
Sep 15, 2026Tobin James RDirectoroption exercise15,000$53.75$806K15,000Sep 16, 2026
Sep 15, 2026Tobin James RDirectoroption exercise15,000$63.68$955K30,000Sep 16, 2026
Sep 15, 2026Tobin James RDirectoropen-market sale30,000$74.58$2M0Sep 16, 2026
Aug 18, 2026Zarrilli Stephen TDirectoroption exercise25,000$53.27$1M25,000Aug 19, 2026
Aug 18, 2026Zarrilli Stephen TDirectoropen-market sale25,000$87.04$2M0Aug 19, 2026
Jul 27, 2026Davidar David DDirectorgift2,500$0.00—507,675Jul 28, 2026
Jun 5, 2026Davidar David DDirectoroption exercise25,000$26.27$657K535,175Jun 9, 2026
Jun 5, 2026Davidar David DDirectoropen-market sale25,000$80.76$2M510,175Jun 9, 2026
Jun 4, 2026Rhoads Ann DDirectoroption exercise25,000$26.27$657K40,384Jun 8, 2026
Feb 25, 2026Huller KellyEVP, GC, Corporate Secretaryoption exercise20,000$43.58$872K20,000Feb 27, 2026
Feb 25, 2026Huller KellyEVP, GC, Corporate Secretaryopen-market sale10b5-120,000$94.50$2M0Feb 27, 2026
Feb 12, 2026Huller KellyEVP, GC, Corporate Secretaryoption exercise10,000$45.64$456K10,000Feb 17, 2026
Feb 12, 2026Huller KellyEVP, GC, Corporate Secretaryopen-market sale10b5-110,000$87.67$877K0Feb 17, 2026
Jan 8, 2026Kline KyleSenior Vice President, CFOoption exercise3,594$51.87$186K3,594Jan 12, 2026
Jan 8, 2026Kline KyleSenior Vice President, CFOopen-market sale10b5-13,594$101.10$363K0Jan 12, 2026
Jan 8, 2026Norwalk Leslie VDirectoropen-market sale10b5-12,000$101.10$202K10,419Jan 12, 2026
Dec 12, 2025Norwalk Leslie VDirectoropen-market sale10b5-14,000$88.85$355K12,419Dec 16, 2025
Dec 8, 2025Paul David CExecutive Chairman, Director, 10% owneroption exercise34,375$25.52$877K60,417Dec 10, 2025
Dec 1, 2025Kline KyleSenior Vice President, CFOoption exercise3,646$53.14$194K3,646Dec 3, 2025
Dec 1, 2025Kline KyleSenior Vice President, CFOoption exercise5,000$56.43$282K8,646Dec 3, 2025
Dec 1, 2025Kline KyleSenior Vice President, CFOoption exercise5,000$64.44$322K13,646Dec 3, 2025
Dec 1, 2025Kline KyleSenior Vice President, CFOoption exercise4,896$63.68$312K18,542Dec 3, 2025
Dec 1, 2025Kline KyleSenior Vice President, CFOopen-market sale10b5-118,542$90.00$2M0Dec 3, 2025
Nov 25, 2025Huller KellySVP, GC, Corporate Secretaryopen-market sale10b5-17,500$90.00$675K0Nov 28, 2025

Full insider history for GLOBUS MEDICAL INC, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
GLOBUS MEDICAL, INC., CIK 1237831 on EDGAR
Extract generated
November 8, 2026
Withheld
7 line-years whose four quarters do not sum to the filed year: cost of revenue FY2018, income tax FY2018, operating income FY2018, opex sga FY2018, other income FY2018, pretax income FY2018, rnd FY2018
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/GMED.json